PHASE-II EVALUATION OF MENOGARIL IN PATIENTS WITH ADVANCED CERVICAL-CARCINOMA - A COLLABORATIVE TRIAL OF THE NORTH-CENTRAL-CANCER-TREATMENT-GROUP AND MAYO-CLINIC

被引：0
|
作者：
LONG, HJ
WIEAND, HS
FOLEY, JF
NIEDRINGHAUS, RD
LAURIE, JA
MORTON, RF
GOLDBERG, RM
MAILLIARD, JA
MALKASIAN, GD
EDMONSON, JH
机构：
[1] MAYO CLIN & MAYO FDN,CTR CANC,STAT UNIT,ROCHESTER,MN 55905
[2] MAYO CLIN & MAYO FDN,DEPT OBSTET & GYNECOL,ROCHESTER,MN 55905
[3] CREIGHTON UNIV,NEBRASKA ONCOL GRP,OMAHA,NE 68178
[4] UNIV NEBRASKA,MED CTR,OMAHA,NE 68105
[5] DULUTH CLIN CCOP,DULUTH,MN 55805
[6] GRAND FORKS CLIN LTD,GRAND FORKS,ND 58201
[7] IOWA ONCOL RES ASSOC CCOP,DES MOINES,IA 50314
[8] GEISINGER CLIN & MED CTR CCOP,DANVILLE,PA 17822
来源：
INVESTIGATIONAL NEW DRUGS | 1991年 / 9卷 / 04期
关键词：
MENOGARIL; CERVIX CANCER; SQUAMOUS CELL CARCINOMA; PHASE-II TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with advanced/recurrent squamous cell carcinoma of the uterine cervix received menogaril, 200 mg/m2 by one hour intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was less than two months and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis occurred at the infusion site in 43% of patients. Menogaril as administered in this protocol is ineffective in treating previously irradiated advanced/recurrent squamous cell carcinoma of the uterine cervix and warrants no further investigation in this disease at the dosage and administration schedule used in this protocol.
引用
收藏
页码：349 / 351
页数：3
相关论文
共 50 条
  • [41] COMPARISON OF COMBINATION CHEMOTHERAPY PROGRAMS IN ADVANCED ADENOCARCINOMA LARGE CELL-CARCINOMA OF THE LUNG - A NORTH-CENTRAL-CANCER-TREATMENT-GROUP STUDY
    KROOK, JE
    FLEMING, TR
    EAGAN, RT
    CULLINAN, S
    PFEIFLE, D
    ELLIOTT, T
    ETZELL, P
    CANCER TREATMENT REPORTS, 1984, 68 (03): : 493 - 498
  • [42] Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma:: an EORTC Gynaecological Cancer Cooperative Group Study
    Lhommé, C
    Vermorken, JB
    Mickiewicz, E
    Chevalier, B
    Alvarez, A
    Mendiola, C
    Pawinski, A
    Lentz, MA
    Pecorelli, S
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (02) : 194 - 199
  • [43] Thalidomide therapy in adult patients with myelodysplastic syndrome - A north central cancer treatment group phase II trial
    Musto, Pellegrino
    CANCER, 2007, 109 (06) : 1211 - 1212
  • [44] Thalidomide therapy in adult patients with myelodysplastic syndrome - A North Central Cancer Treatment Group Phase II trial
    Moreno-Aspitia, Alvaro
    Colon-Otero, Gerardo
    Hoering, Antje
    Tefferi, Ayalew
    Niedringhaus, Robert D.
    Vukov, Allen
    Li, Chin-Yang
    Menke, David M.
    Geyer, Susan M.
    Alberts, Steven R.
    CANCER, 2006, 107 (04) : 767 - 772
  • [45] PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074
    Uhm, Joon H.
    Ballman, Karla V.
    Wu, Wenting
    Giannini, Caterina
    Krauss, J. C.
    Buckner, Jan C.
    James, C. D.
    Scheithauer, Bernd W.
    Behrens, Robert J.
    Flynn, Patrick J.
    Schaefer, Paul L.
    Dakhill, Shaker R.
    Jaeckle, Kurt A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (02): : 347 - 353
  • [46] Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A north central cancer treatment group phase II trial
    Alberts, SR
    Schroeder, M
    Erlichman, C
    Steen, PD
    Foster, NR
    Moore, DF
    Rowland, KM
    Nair, S
    Tschetter, LK
    Fitch, TR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) : 4944 - 4950
  • [47] PHASE-II EVALUATION OF CISPLATIN IN SQUAMOUS CARCINOMA OF THE ESOPHAGUS - A SOUTHEASTERN CANCER STUDY-GROUP TRIAL
    RAVRY, MJR
    MOORE, MR
    OMURA, GA
    ESSEESE, I
    BARTOLUCCI, A
    CANCER TREATMENT REPORTS, 1985, 69 (12): : 1457 - 1458
  • [48] PHASE-II TRIAL OF PIPERAZINEDIONE IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    THIGPEN, JT
    BLESSING, JA
    HOMESLEY, HD
    PETTY, W
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (01): : 21 - 23
  • [49] PHASE-II TRIAL OF ADRIAMYCIN IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - GYNECOLOGIC ONCOLOGY GROUP-STUDY
    THIGPEN, JT
    BUCHSBAUM, HJ
    MANGAN, C
    BLESSING, JA
    CANCER TREATMENT REPORTS, 1979, 63 (01): : 21 - 27
  • [50] Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group.
    Ingle, JN
    Rowland, KM
    Suman, VJ
    Mirchandani, D
    Bernath, AM
    Camoriano, JK
    Perez, EA
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S38 - S38
12345